Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients:A Population-Based Study by Leal, J. et al.
                          Leal, J., Gray, A. M., Hawley, S., Prieto-Alhambra, D., Delmestri, A., Arden,
N. K., ... Judge, A. (2017). Cost-Effectiveness of Orthogeriatric and Fracture
Liaison Service Models of Care for Hip Fracture Patients: A Population-
Based Study. Journal of Bone and Mineral Research, 32(2), 203-211.
https://doi.org/10.1002/jbmr.2995
Publisher's PDF, also known as Version of record
License (if available):
Other
Link to published version (if available):
10.1002/jbmr.2995
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.2995 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Cost-Effectiveness of Orthogeriatric and Fracture Liaison
Service Models of Care for Hip Fracture Patients:
A Population-Based Study
Jose Leal,1 Alastair M Gray,1 Samuel Hawley,2 Daniel Prieto-Alhambra,2,3,4 Antonella Delmestri,2
Nigel K Arden,2,3 Cyrus Cooper,2,3 M Kassim Javaid,2,3 Andrew Judge2,3; and the REFReSH Study Group
1Health Economics Research Centre, Nufﬁeld Department of Population Health, University of Oxford, Oxford, UK
2Oxford NIHR Musculoskeletal Biomedical Research Unit, Nufﬁeld Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,
University of Oxford, Oxford, UK
3MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK
4GREMPAL Research Group (Idiap Jordi Gol) and Musculoskeletal Research Unit (Fundacio IMIM-Parc Salut Mar), Universitat Autonoma de
Barcelona, Barcelona, Spain
ABSTRACT
Fracture liaison services are recommended as amodel of best practice for organizing patient care and secondary fracture prevention
for hip fracture patients, although variation exists in how such services are structured. There is considerable uncertainty as to
which model is most cost-effective and should therefore be mandated. This study evaluated the cost-effectiveness of orthogeriatric
(OG)- and nurse-led fracture liaison service (FLS) models of post-hip fracture care compared with usual care. Analyses were
conducted from a health care and personal social services payer perspective, using aMarkovmodel to estimate the lifetime impact of
the models of care. The base-case population consisted of men and women aged 83 years with a hip fracture. The risk and costs of
hip and non-hip fractures were derived from large primary and hospital care data sets in the UK. Utilities were informed by a meta-
regression of 32 studies. In the base-case analysis, the orthogeriatric-led service was the most effective and cost-effective model of
care at a threshold of £30,000 per quality-adjusted life years gained (QALY). For women aged 83 years, the OG-led service was the
most cost-effective at £22,709/QALY. If only health care costs are considered, OG-led service was cost-effective at £12,860/QALY and
£14,525/QALY for women andmen aged 83 years, respectively. Irrespective of how patients were stratiﬁed in terms of their age, sex,
and Charlson comorbidity score at index hip fracture, our results suggest that introducing an orthogeriatrician-led or a nurse-led FLS
is cost-effectivewhen comparedwith usual care. Although considerable uncertainty remains concerningwhich of themodels of care
should be preferred, introducing an orthogeriatrician-led service seems to be the most cost-effective service to pursue. © 2016
American Society for Bone and Mineral Research.
KEY WORDS: COST-EFFECTIVENESS; OSTEOPOROSIS; HIP FRACTURE; SECONDARY PREVENTION; FRACTURE LIAISON SERVICE; NATURAL
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Introduction
Hip fractures are a major public health problem, with highmorbidity, mortality, and health and social care costs.(1–3) In
the UK, hip fractures account for £1.1 billion per year in hospital
costs,(4) which is expected to rise to £1.5 billion by 2025(4) when
104,000 annual cases are predicted.(3) A previous study showed
that acute hospital admission resulting from hip fracture was the
largest component of hospital costs, with higher costs and
length of stay for second compared with index hip fractures.(4)
There is therefore a strong economic incentive to identify and
implement cost-effective measures for the provision of timely
patient care and secondary fracture prevention after an index
hip fracture.
Fracture liaison services are recommended as a model of
best practice for patients with hip fracture. This is supported
by international guidance,(5,6) patient organizations, the UK
Department of Health,(7,8) and several UK national bodies
(British Orthopaedic Association,(9) NICE,(10) National Osteopo-
rosis Society, and Age UK(11)). The proposed model consists of
two main stages of care: 1) orthogeriatric services focusing on
achieving optimal recovery after hip fracture, and 2) nurse-led
fracture liaison services focusing on secondary fracture preven-
tion of fragility fractures.
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The Glasgow Fracture Liaison Service(12) reported that for
every 1000 patients with a fragility fracture assessed by that FLS,
18 fragility fractures (including 11 hip fractures) were prevented.
However, no ﬁrm evidence or evidence-based consensus exists
as towhich caremodel should bemandated across the NHS. As a
result, current practice reﬂects signiﬁcant variations across NHS
hospital providers in the adoption and organization of FLS.(13)
We used large health care data sets based on deidentiﬁed
computerized records, together with a detailed evaluation of
hospital hip fracture services in a UK region,(14) to estimate the
“real-world” impact of the different models of care in terms of
morbidity, survival, and costs, and to determine the cost-
effectiveness of orthogeriatric (OG)- and nurse-led fracture
liaison service (FLS) models of care after hip fracture compared
with usual care in the English NHS.
Materials and Methods
Decision model and models of care
We estimated the cost-effectiveness of the following models of
care for all patients with a hip fracture admitted to an NHS
hospital: 1) Introduction of an orthogeriatrician-led (OG) model
of post-hip fracture care; 2) Introduction of a nurse-led fracture
liaison (FLS) model of post-hip fracture care; 3) Standard post-
hip fracture care.
These models of care reﬂect the services provided in one
regional area in the UK that comprises 11 hospitals receiving
patients with acute hip fractures. Details on the OG and FLS
models delivered within the region from 2003 to 2013 have
been published elsewhere.(14,15) Brieﬂy, although there was
variation across hospitals, the introduction of the OG model
involved the appointment of an orthogeriatrician as the clinical
lead, responsible for case ﬁnding, preoperative assessment,
patient assessment, and treatment initiation, as well as having
involvement in postoperative care. The average staff level of an
OG for secondary fracture prevention services was estimated at
0.75 whole time equivalents (WTE) within region. The FLS model
involved the appointment of a nurse specialist (osteoporosis or
trauma) responsible for case ﬁnding, assessment, treatment
recommendations, medication assessment, and preparation of
the follow-up plan, as well as for providing additional support for
management of bone health in hospital. In this region of the UK,
treatment adherence monitoring was predominately delegated
to primary care. Finally, standard care post-hip fracture care
reﬂects care provided without the introduction and/or expan-
sion of OG and FLS models of care.
The perspective adopted was that of the NHS in England and
personal social services, including primary and secondary health
care and care home costs. Primary care costs included GP and
practice nurse contacts, visits to other community health care
professionals (eg, health visitor, physiotherapist), laboratory
tests, and drugs. Secondary health care costs included
outpatient visits, accident and emergency contacts, day cases,
and inpatient admissions. Primary and secondary care costs
captured hip fracture–related costs as well as all other costs. We
did not include the cost of walking aids, home adaptation costs,
or home care costs funded by councils or local organizations
(eg, live-in help, meals, nursing care, domestic help, etc.).
Given the natural history of hip fracture progression with
recursive events, a Markov model was built to evaluate
the lifetime costs (quality-adjusted) life expectancy and cost-
effectiveness. The model structure was deﬁned using an
iterative process involving discussions with clinical experts
and epidemiologists involved in the REFRESH study and
supplemented by a literature review of economic models in
the disease area.
The Markov model, developed in Excel (Microsoft, Redmond,
WA, USA), was used to simulate the natural history of individuals
after an index hip fracture across health states representing:
history of index hip fracture, second hip fracture; major non-hip
fracture(s) (pelvic, spine, wrist, humerus, and rib) requiring
hospitalization; living in patient’s own home or in a care home;
and dead (within 30 days post-hip fracture or within year) (Fig. 1
and Supplemental Fig. S1). We assumed that if a patient
transitioned to a care home they would not go back to their own
home for the remainder of their life. A cycle length of one year
was considered appropriate given the natural history of hip
fracture patients, and half-cycle correction was performed.(16) All
costs and outcomes were discounted using the recommended
annual rate of 3.5%. Costs are quoted in 2012/2013 prices.
Derivation of model inputs
Study subjects in Hospital Episode Statistics (HES) data set
We extracted all hospital records for 33,152 patients older than
60 years who had had an emergency hospital admission with a
primary ICD-10 diagnosis code for hip fracture (S72.0, S72.1,
S72.2, and S72.9) between April 2003 and March 2013 for a
representative region of the UK (Fig. 2 and Supplemental
Table S1).(4) The HES data were used to develop the risk
equations for the following events: time to second hip fracture,
time tomajor non-hip fragility fracture requiring hospitalization,
discharge to care home (nursing or residential) after hip fracture,
and time to death. The data were also used to estimate the
annual hospitalization costs for each health state of the model.
See Supplemental Material and Leal and colleagues(4) for details
on the valuation of hospital resource use.
Study subjects in the Clinical Practice Research Datalink (CPRD)
data set
We extracted all primary care contacts, laboratory tests, and
prescribed drugs for 4063 patients registered in the CPRD GOLD
database between April 1, 2003, and March 31, 2012, who had
linked hospital use records indicating a hip fracture (Fig. 2 and
Supplemental Table S2). Hip fracture was identiﬁed in primary
care records using predeﬁned READ codes (Supplemental
Table S3). The data set was used to estimate the annual primary
care costs for each health state of the model. Resource use was
valued using national cost databases for the year 2012/13(17–19)
(see Supplemental Table S4 for more details).
Relative effectiveness of OG and FLS
Previous work using the HES cohort(15) informed the relative
effectiveness of the models of care measured by time to second
hip fracture (hazard ratio [HR]) and time to death (HR) adjusted
for confounding factors such as age, sex, deprivation, and
Charlson comorbidity index (Table 1). In the base case, we
assumed the effect of introducing OG or FLS relative to usual
care on mortality after hip fracture was present only for the
index fracture and in the year of the fracture, and the effect on
second hip fracture was present only in the ﬁrst 2 years after
index hip fracture. These assumptions were explored in
sensitivity analysis.
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Cost of introducing OG and FLS
Based on the survey of 11 hospitals in the UK region(14) reporting
stafﬁng levels and non-clinical activities (eg, clinical leadership
roles) of an orthogeriatrician and a nurse leading the FLS within
the same region, an FLS was assumed to operate at 100%
capacity (whole time equivalent [WTE]), whereas an OG was
assumed to operate at 75% capacity. The annual costs of an OG
and an FLS per hip fracture patient were estimated by
multiplying the respective WTE by the total annual costs(18)
and dividing these by 450 hip fracture patients (average patients
seen per year across the 11 hospitals in the survey(20)) (Table 1).
Fig. 1. Model structure and allowed transitions in the ﬁrst year of simulation. Themodel simulated the transition of a cohort of patients with an index hip
fracture through the health states over time to estimate expected costs and outcomes. At the start of the simulation, patients with a hip fracture could die
within 30 days or be discharged home or to a care home (nursing or residential care home). In the same cycle, patients could then develop a second hip
fracture, other major fragility fracture requiring hospitalization (non-hip such as pelvic, spine, wrist, humerus, and rib), have no further events, or die. If
patients experienced a second hip fracture, they could die within 30 days or, if alive, be discharged to a care home or their own home.
Fig. 2. Identiﬁcation of patients with hip fracture in the HES and CPRD data sets.
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The OG- and FLS-speciﬁc costs were assumed to occur in the
year of the index hip fracture, which was explored in sensitivity
analysis.
Statistical analysis
The rate of second hip fracture or of major non-hip fracture
requiring hospitalization after the index fracture was estimated
using parametric survivalmodels. Time to event was determined
in continuous time from the onset of ﬁrst hip fracture, using
the censor date of death or the date of administrative
censoring (March 31, 2013). All-cause mortality was derived
using two logistic models to capture the high mortality in the
ﬁrst 30 days after ﬁrst and second hip fracture (separate
models) and a Gompertz proportional hazards survival model
for the subsequent years. Time to death was modeled in
continuous time, using each patient’s current age as time at
risk to better extrapolate beyond the observed follow-up
period.(21) Logistic models estimated the probability of
admission to care home (nursing or residential) after hip
fracture (index and second). A generalized linear model (GLM),
with a gamma distribution and identity link function, was used
to predict the annual primary and hospital care costs by
health state. Time-invariant covariates included sex, age, and
Charlson comorbidity index at ﬁrst hip fracture, and time-
variant factors included occurrence or history of second hip
fracture, occurrence or history of major non-hip fracture, and
admission from care home or own home. The proportion of
those discharged to a care home that go to a nursing home
was derived from the National Hip Fracture Database report(20)
and costed using a national cost database(18) (Table 1).
Statistical analysis was carried out using Stata v. 12 (StataCorp,
College Station, TX, USA). See Supplemental Material for more
methodological details.
Table 1. Model Parameters
Parameter Mean (95% CI) Source
Relative effectiveness (hazard ratio)
Introducing OG relative to usual care
30-day mortality after index hip fracture 0.73 (0.65–0.82) Hawley(15)
1-year mortality after index hip fracture 0.81 (0.75–0.87) Hawley(15)
2-year risk of developing second hip fracture 0.95 (0.79–1.15) Hawley(15)
Introducing FLS relative to usual care
30-day mortality after index hip fracture 0.80 (0.71–0.91) Hawley(15)
1-year mortality after index hip fracture 0.84 (0.77–0.93) Hawley(15)
2-year risk of developing second hip fracture 1.03 (0.85–1.26) Hawley(15)
Discharge to care home after index hip fracture
(previously not in care home)
Supplemental Table S8 HES
Discharge to care home after second hip fracture
(previously not in care home)
Supplemental Table S8 HES
Risk of second hip fracture Supplemental Table S9 HES
Risk of major non-hip fracture requiring hospitalization Supplemental Table S9 HES
30-day mortality after index hip fracture Supplemental Table S9 HES
30-day mortality after second hip fracture Supplemental Table S9 HES
All-cause mortality post 30 days of fracture Supplemental Table S9 HES
Intervention costa
Fracture liaison nurse (grade 7) per hip fracture patient £200 Curtis(18)
Orthogeriatrician (consultant) £420 Curtis(18)
Proportion discharged to a care home that go to a
nursing home
0.48 (0.47–0.49) National Hip Fracture
Database(20)
Primary care costs in year of index fracture Supplemental Table S10 CPRD
Primary care costs in years after index fracture Supplemental Table S10 CPRD
Hospitalization costs in year of index hip fracture Supplemental Table S11 HES
Hospitalization costs in year of second hip fracture Supplemental Table S11 HES
Hospitalization costs in years after fracture Supplemental Table S11 HES
Hospitalization costs if non-hip fracture occurs Supplemental Table S12 HES
Hospitalization costs if death occurs Supplemental Table S12 HES
Cost of institutionalization (per year)b
Nursing home £39,000 Curtis(18)
Residential home £27,664 Curtis(18)
Utility of hip fracture patients
Within 1 month of index fracture 0.46 (0.38–0.55) Lit review
At 12 months 0.53 (0.47–0.61) Lit review
At 24 months and after 0.66 (0.60–0.74) Lit review
Discount rate for costs and outcomes 3.5% HM Treasury
HES¼Hospital Episode Statistics database; CPRD¼Clinical Practice Research Datalink database.
aIncludes salary, salary oncosts, qualiﬁcation costs, management and non-staff overheads, and capital overheads.
bNursing home at £39,000 per year (£750 per week times 52 weeks) and residential home at £27,664 per year (£532 per week times 52 weeks).
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Quality of life in patients with hip fracture
We used ameta-regression approach, with a linearmixed-effects
model, to synthesize absolute utility data from 32 studies
(21,085 patients) identiﬁed by literature review, which reported
preference-based quality of life for patients with hip fracture (eg,
EQ-5D, EQVAS, HUI2, etc.) (Supplemental Fig. S2 and Supple-
mental Table S5). The resulting model was used to predict the
EQ-5Dutility values of hip fracture patients at several time points
(onset and 1, 6, 12, 18, 24 months) to estimate utility up to
2 years after hip fracture using the area under the curve (Table 1).
We assumed that utilities remained constant after the ﬁrst year
after hip fracture (ie, 0.66) and that second hip fractures and
major non-hip fractures requiring hospitalization had the same
utility in the year of the event as those at the onset of hip fracture
(0.46). These assumptions were varied in sensitivity analyses.
Analysis
Two cohorts of 1000 identical men and women were used to
simulate a representative patient aged 83 years at hip fracture,
with an average pre-admission Charlson comorbidity score of 1.2
and living in their own home before the fracture. We further
assessed the cost-effectiveness of the models of care in several
subgroups of hip fracture patients deﬁned according to their age,
sex, andCharlsoncomorbidity scoreat indexhip fracture. Amodel
of care was deemed to be cost-effective if the incremental cost-
effectiveness ratio (ICER) was below £30,000 per quality-adjusted
life years (QALY) gained.(22) The ICER was estimated by dividing
the difference inmean costs by thedifference inmean effects (life
years andQALYs) for a givenmodel of care comparedwith its next
best alternative. Internal validity of themodel was checked using
sensitivity analysis (extreme values) and by comparing themodel
outputswith the data used to build themodel. Model parameters
and structural assumptions were evaluated in one-way and
probabilistic sensitivity analysis and quantiﬁed using a cost-
effectiveness acceptability curve (CEAC)(23) and analysis of
covariance methods (ANCOVA)(24) (see Supplemental Material).
Key uncertainties in the model structure were identiﬁed when
developing the conceptual framework.
Results
Risk and cost equations
The mean follow-up time of patients in the HES data set was 2.6
years (SD 2.5) after index hip fracture, and 84,717 patient-years
of data were available to estimate the risk equations. The
number of patients reporting second hip fracture and major
non-hip fractures were 2206 and 1464, respectively (Supplemen-
tal Table S7). Supplemental Tables S8 and S9 report the risk
models, and Supplemental Tables S10–12 report the costmodels.
These models allow simulating the natural history of individuals
and costs as well as patient heterogeneity. For example, being
female was associated with higher risk of second hip fracture,
higher risk of major non-hip fracture, lower risk of mortality
(Supplemental Table S9), lower risk of hospitalization, and lower
hospital costs (Supplemental Table S10), adjusting for other
covariates. Patients living in a care home were associated with a
higher risk of major non-hip fracture, higher risk of mortality
(Supplemental Table S9), higher risk of hospital admission, and
higher hospital costs if admitted, as well as higher primary care
costs in the year of the hip fracture (Supplemental Tables S10
and S11), adjusting for other covariates.
Representative patient—male
Table 2 reports the total life years, QALYs, and costs associated
with each of the three models of care. For our male cohort of
1000, the introduction of an OG and FLS would result in a
reduction of 26 (95% conﬁdence interval [CI] 17–35) and 19
(95% CI 9–29) deaths within 30 days of primary hip fracture,
respectively, compared with usual care (Supplemental
Table S13). Within 1 year of primary hip fracture, the reduction
in deaths by introducing an OG and FLS, compared with usual
care, would be 58 (95% CI 44–71) and 46 (95%CI 28–63),
respectively. On average, over the lifetime of a patient, when
compared with usual care, we would expect each patient to
experience an increase of 0.18 (95% CI 0.14–0.23) and 0.14
(95% CI 0.08–0.19) life years (undiscounted) spent in their own
home if an OG or FLS were to be introduced, respectively.
Relative to usual care, the mean discounted health care and
care home costs would be £2610 (95% CI £2109–£3166) and
£1975 (95% CI £1265–£2591) higher when an OG or FLS were
introduced, respectively. Higher care home costs accounted for
35% and 44% of the additional costs of FLS and OG, respectively.
This was a result of increased longevity due to OG or FLS being
introduced. The discounted average QALYs gained by male
patients, relative to usual care, were 0.13 (95% CI 0.09–0.16) and
0.10 (95% CI 0.06–0.14) if an OG or FLS were to be introduced,
respectively.
At a £30,000 per QALY threshold, the most cost-effective
model of care was introducing an orthogeriatrician, with an ICER
of £23,407/QALY (Table 3). There was considerable uncertainty
regarding the comparison between OG and FLS models of care
with statistically nonsigniﬁcant difference in costs and QALYs
being £635 (95% CI –£207 to £1496) and 0.03 (95% CI –0.02 to
0.07), respectively (Table 3 and Supplemental Fig. S3). However,
the probability that introducing OG-led FLS was the most cost-
effective option was estimated at 69%.
Representative patient—female
For our female cohort of 1000, mortality at 30 days and within
1 year was lower compared with the male cohort in the usual
care (Supplemental Table S13). Hence, the introduction of an OG
and FLS would result in a reduction of 16 (95% CI 11–22) and 12
(95% CI 5–18) deaths within 30 days of primary hip fracture,
respectively, compared with usual care. Within 1 year of primary
hip fracture, the reduction in deaths by introducing an OG and
FLS, compared with usual care, was 42 (95% CI 31–51) and 33
(95% CI 21–45), respectively. On average, over a lifetime, when
compared with usual care, we would expect each female to
experience an increase of 0.17 (95% CI 0.13–0.21) and 0.13 (95%
CI 0.08–0.18) life years (undiscounted) spent in their own home if
an OG or FLS were to be introduced, respectively.
The mean discounted health care and care home costs were
£2547 (95% CI £1993–£3035) and £1909 (95% CI £1272–£2515)
higher by introducing an OG and FLS, respectively, relative to
usual care. As a result of longer longevity relative to males, care
home costs now accounted for 41% and 51% of the additional
costs of FLS and OG, respectively. The discounted average
QALYs gained by female patients, relative to usual care, were
0.12 (95% CI 0.09–0.15) and 0.09 (95% CI 0.06–0.13) if an OG or
FLS were to be introduced, respectively.
At a £30,000 per QALY threshold, the most cost-effective
model of care for females was introducing an orthogeriatrician,
with an ICER of £22,709/QALY (Table 3). As with males,
considerable uncertainty exists when comparing OG and FLS
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models of care with again nonsigniﬁcant differences in costs
andQALYs: £638 (95%CI –£207 to £1,418) and 0.03 (95%CI –0.02
to 0.07), respectively (Table 3 and Supplemental Fig. S4). Finally,
the probability that introducing OG-led service was the most
cost-effective option was estimated at 72%.
Sensitivity analysis
Fig. 3 reports the impact of uncertainty in different parameters
on the uncertainty of incremental costs and QALYs of
introducing an orthogeriatrician compared with FLS. This was
Table 3. Cost-Effectiveness of the Differing Models of Secondary Prevention Care of Hip Fractures
Difference
in costs
Difference
in LYs
Difference
in QALYs
ICER
(£/LY)
ICER
(£/QALY)
Probability that is the
most cost-effective
at £30,000/QALY
Representative male Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean Mean
Usual care — — — — — 0%
FLS versus usual care £1,975 (1297
to 2620)
0.159 (0.095
to 0.218)
0.099 (0.058
to 0.140)
£12,458 £19,955 31%
OG versus fracture
liaison nurse
£635 (207
to 1496)
0.043 (0.031
to 0.116)
0.027 (0.019
to 0.074)
£14,898 £23,407 69%
Representative female
Usual care — — — — — 0%
FLS versus usual care £1,909 (1271
to 2562)
0.149 (0.094
to 0.209)
0.093 (0.057
to 0.133)
£12,837 £20,421 28%
OG versus fracture
liaison nurse
£638 (207
to 1418)
0.044 (0.032
to 0.110)
0.028 (0.020
to 0.071)
£14,618 £22,709 72%
LY¼ life years; QALY¼quality-adjusted life years; ICER¼ incremental cost-effectiveness ratio; FLS¼ fracture liaison service; OG¼ orthogeriatric.
Table 2. Mean Discounted Costs and Outcomes of the Differing Models of Secondary Prevention Care
Usual care Fracture liaison nurse Orthogeriatrician
Representative malea Mean (95%CI) Mean (95%CI) Mean (95%CI)
Total costs £39,069 £41,044 £41,679
(£37,798–£40,514) (£39,495–£42,621) (£40,265–£43,262)
Intervention 0 £200 £420
Hospital care £23,025 £23,678 £23,814
(£22,406–£23,679) (£22,988–£24,384) (£23,132–£24,525)
Primary care £3,276 £3,471 £3,523
(£3046–£3490) (£3234–£3714) (£3285–£3762)
Care home £12,767 £13,695 £13,922
(£11,893–£13,817) (£12,689–£14,837) (£12,962–£15,039)
Total life years 2.68 2.83 2.88
(2.56–2.79) (2.70–2.96) (2.75–3.00)
Total QALYs 1.64 1.74 1.77
(1.46–1.83) (1.54–1.96) (1.56–1.98)
Representative femalea
Total costs £50,534 £52,444 £53,081
(£49,226–£52,276) (£50,935–£54,340) (£51,559–£54,974)
Intervention 0 £200 £420
Hospital care £23,893 £24,387 £24,478
(£23,390–£24,471) (£23,804–£25,040) (£23,918–£25,073)
Primary care £4,721 £4,902 £4,955
(£4417–£5016) (£4571–£5224) (£4635–£5265)
Care home £21,921 £22,955 £23,229
(£20,972–£23,134) (£21,925–£24,301) (£22,191–£24,524)
Total life years 3.89 4.04 4.09
(3.77–4.03) (3.91–4.19) (3.95–4.24)
Total QALYs 2.42 2.52 2.54
(2.15–2.72) (2.23–2.82) (2.26–2.85)
aAged 83 years at hip fracture, with an average pre-admission Charlson-comorbidity score of 1.2 and living in their own home before the fracture.
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largely associated with the uncertainty in the relative effective-
ness of an OG-led model of care compared with FLS on 30-day
(accounting for 25% of all uncertainty in incremental costs and
QALYs) and 1-year mortality (52% to 58% of all uncertainty) after
index hip fracture. The uncertainty in the natural history
components of the model (eg, absolute mortality, probability
of second hip fracture, or other major fragility fracture) was
associated with 10% of all uncertainty in the incremental costs
and QALYs. In terms of model structural assumptions, we
tested the impact of changes to these assumptions on the
cost-effectiveness results (Supplemental Table S14). Overall, at
a £30,000/QALY threshold, the introduction of OG or FLS
relative to usual care remained the most cost-effective options
when the assumptions were changed. For example, assuming
the effect of the interventions concerning second hip fracture
extended over lifetime rather than 2 years resulted in OG
becoming more cost-effective (£20,036/QALY). Also, assuming
that the effect of the interventions on mortality extended
over lifetime rather than 1 year after hip fracture resulted in
OG being more cost-effective (£18,052/QALY). Excluding care
home costs resulted in OG becoming more cost-effective
(£13,039/QALY and £14,733/QALY for women and men,
respectively). Assuming that the OG and FLS services resulted
in additional £1000 per patient in management and test costs
during the hip fracture admission relative to usual care resulted
in OG becoming borderline cost-effective (£29,573/QALY).
Finally, using the smallest hospital in the UK region (220 hip
fractures per year) to estimate the intervention cost per
patient (OG at £859 per patient and FLS at £409 per patient)
resulted in FLS becoming the most cost-effective option (ICER
of £22,922/QALY; Supplemental Table S14).
Subgroup analysis
For patients up to age 80 years, introducing an OG was the most
cost-effective option (Supplemental Table S15). In contrast,
introducing an FLS became the most cost-effective option for
patients aged 90 years if their Charlson comorbidity score at
index hip fracture was 5 or above.
Discussion
Our cost-effectiveness analysis of models of hip fracture care
found that the introduction and/or expansion of OG- and nurse-
led FLS was more effective and cost-effective than usual care.
Two recent systematic reviews assessed the economic
evidence concerning the prevention of osteoporotic frac-
tures.(25,26) Consistent with our ﬁndings, three previous
economic evaluations, using Markov models, reported second-
ary fracture prevention interventions (ie, hospital osteoporosis
casemanager, outpatient-based FLS, and hospital nurse-led FLS)
to be cost-effective in populations with fragility fracture.(12,27,28)
These analyses were limited by the use of data from single
institutions and by a relatively short follow-up period (up for 1
year) or by the use of disparate data sources covering different
populations of patients and time periods. Our study beneﬁtted
from the availability of large primary and hospital data sets to
robustly estimate the impact of themodels of care across a large
representative population in terms of survival, prevention of
second hip fracture, primary care and hospital care costs, and
cost-effectiveness. For example, having incorporated into our
modeling robust estimates of the time to second hip fracture
and death and the short- and long-term costs associated with
patients with hip fracture, we did not ﬁnd the introduction and/
or expansion of OG- or nurse-led services to be cost-saving
compared with usual care, in contrast to previous work.(12,27)
This is largely explained by the added longevity that translates
into higher costs and refractures compared with usual care.
Irrespective of how patients were stratiﬁed in terms of their
age, sex, and Charlson comorbidity score at index hip fracture,
our results suggest that it is cost-effective to introduce an
orthogeriatrician or FLS compared with usual care. We ﬁnd that
these models of care produce greater gains in life years than
QALYs, suggesting that the positive impact on survival was not
necessarily accompanied by proportional gains in quality of life.
This is an area that would repay closer investigation.
There is considerable uncertainty in the evidence informing
the model, particularly concerning the relative effectiveness of
an OG- compared with a nurse-led FLS on survival and
prevention of second hip fracture and also concerning the
natural history of hip fracture. The large number of hip fractures
every year for which these interventions are potentially relevant
suggests that caution is required about decisions based on the
model results. Our ﬁndings highlight the need for further
research to reduce decision uncertainty, with particular
emphasis on undertaking clinical trials to obtain unbiased
comparisons of the different models of secondary care services.
The translation of our ﬁndings into other types of acute
fragility fractures requiring inpatient care is possible. However,
the management of vertebral fractures requires additional
components, different mechanisms for case ﬁnding (routine
VFA, text mining radiology reports, rereading axial imaging) as
well as treatment (analgesia, vertebral augmentation) relative to
hip fractures. Although these types of care pathways can be
delivered within an FLS system, they require layering of
additional work ﬂows and remain a priority for future service
development.(29)
Furthermore, the case-mix of patients seen by the OG- and
nurse-led FLS services may vary by type of fracture and frailty of
Fig. 3. Orthogeriatrician- versus nurse-led fracture liaison service:
ANCOVA analysis of proportion of sum of squares for incremental QALYs
saved and incremental costs explained by the uncertainty in the model.
The horizontal axis represents the variation in incremental costs and
QALYs that is associated with the uncertainty in the model inputs.
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patient; however, our qualitative evaluation of hip fracture
services within the region did not detect differences in the types
of patients that were seen by OG and FLS models of care.(14)
Our study had several limitations. First, althoughwe improved
on previous studies by basing our estimates of effectiveness on a
very large administrative data set supported by a careful survey
of the services provided in each hospital,(14,15) there were no
effectiveness data informed by clinical trials, and the limited
range and number of services currently provided in England
precluded considering somemodels of care, such as introducing
a combined orthogeriatrician- and nurse-led FLS. Second, we did
not separate the different types of fragility-related fractures that
patients could suffer post-discharge. We focused on major non-
hip fractures requiring hospitalization given their relative large
impact in terms of health care costs. Furthermore, we did not
separate non-hip fractures by type so that we could beneﬁt from
a larger sample to estimate the costs. Nonetheless, other fragility
fractures not incurring hospitalization were still captured in the
model in the primary and hospital care costs. Third, we did not
have quality-of-life data from individual patient records and
relied instead on a systematic review and meta-regression of
published literature. This provided estimates of changes in EQ-
5D-based utility conditional on time since hip fracture, but we
could not reliably estimate utility values for non-hip fractures or
the additional impact these may have on the quality of life of
individuals with a history of hip fracture. The consequent
assumptions were explored in sensitivity analysis, but future
research could address this limitation. Furthermore, the use of a
cohort-based Markov model made it difﬁcult to capture the
trajectory of utility values taking into account both time since
primary hip fracture and history of events such as non-hip
fractures and second hip fracture. An individual-based (ie,
microsimulation) Markov model would have facilitated tracking
of each individual’s history and time-varying utility values, but
would have been more time-consuming to construct and
computationally intensive to run.(30) Finally, we only included
health care and care home costs, and so excluded some
important economic considerations for people with hip fracture
and their families, such as unpaid care provided by friends and
family, walking aids, and home adaptation costs as a conse-
quence of the fracture, as well as locally funded home social care
(eg, provision of meals, nursing care, live-in help, etc.). Future
research using UK-based populations of hip fracture patients is
needed to assess the use and costs of these resources as well as
the impact on informal care.
In conclusion, our work suggests that it is cost-effective to
introduce an orthogeriatrician or FLS secondary care service for
patients with a hip fracture, predominantly because of their
effects onmortality rather than on refracture. Further research is
needed to make more informed decisions with a focus on
estimating the effectiveness of thesemodels of care informed by
clinical trials.
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